{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001173313","name":"ABVC BIOPHARMA, INC.","summary":"ABVC BioPharma is an early-stage biotechnology company developing a pipeline of seven new drugs and one medical device, all licensed from related parties. Its pipeline targets CNS disorders (major depressive disorder, ADHD) and oncology/hematology (lung cancer, pancreatic cancer, cancer-related depression). Revenue comes from outlicensing intellectual properties and CDMO services via its subsidiary BioKey, which also manufactures maitake mushroom dietary supplements.","people":[],"products":[{"name":"ABV-1504","type":"platform","description":"Botanical norepinephrine reuptake inhibitor for Major Depressive Disorder, Phase II completed."},{"name":"ABV-1505","type":"platform","description":"Botanical drug for adult ADHD, Phase II Part 2 ongoing at UCSF and Taiwan sites."},{"name":"ABV-1601","type":"platform","description":"NCE drug for Major Depression in Cancer Patients, Phase I/II at Cedars Sinai Medical Center."},{"name":"ABV-1701 (Vitargus)","type":"hardware","description":"Medical device for vitrectomy surgery, Phase II initiated in Australia and Thailand."},{"name":"ABV-1519","type":"platform","description":"Drug for Non-Small Cell Lung Cancer, Phase I/II expected to begin Q3 2026 in Taiwan."},{"name":"ABV-1703","type":"platform","description":"Drug for advanced inoperable or metastatic pancreatic cancer, Phase II expected Q3 2026."},{"name":"Maitake Mushroom Supplement","type":"platform","description":"Dietary supplement in tablet and liquid form manufactured by BioKey for US, Canada, Taiwan, and China markets."},{"name":"CDMO Services","type":"service","description":"Contract development and manufacturing services for clinical trial drugs via BioKey GMP facility."}],"partnerships":[{"partner_name":"Stanford University Medical Center","partnership_type":"development","description":"Principal investigators Charles DeBattista and Alan Schatzberg conducting ABV-1504 Phase II trial.","start_date":null},{"partner_name":"University of California San Francisco (UCSF)","partnership_type":"development","description":"Principal investigators conducting ABV-1505 Phase II adult ADHD clinical trials.","start_date":null},{"partner_name":"Cedars Sinai Medical Center","partnership_type":"development","description":"Principal investigators for ABV-1601 (Phase I/II) and ABV-1703 (Phase II) clinical trials.","start_date":null},{"partner_name":"Ramathibodi Hospital / Srinagarind Hospital","partnership_type":"development","description":"Thailand sites for ABV-1701 Vitargus Phase II vitrectomy surgery study.","start_date":null},{"partner_name":"Sydney Eye Hospital / East Melbourne Eye Group","partnership_type":"development","description":"Australian sites for ABV-1701 Vitargus Phase II study.","start_date":null},{"partner_name":"Taipei Veterans General Hospital","partnership_type":"development","description":"Site for ABV-1504, ABV-1505, and ABV-1519 clinical trials in Taiwan.","start_date":null},{"partner_name":"Define Biotech Co. Ltd.","partnership_type":"licensing","description":"Three-year exclusive distribution agreement (auto-renewed through December 2026) for maitake supplement in China and Taiwan, $3M purchase commitment.","start_date":null},{"partner_name":"Shogun Maitake Canada, Co. Ltd.","partnership_type":"strategic","description":"Supplier of maitake mushrooms for BioKey's dietary supplement manufacturing.","start_date":null}],"affiliations":[],"origin":{"leaf":"b4541fce8f5d005f98162972d526b1dc67256c1c8fdaa6191ea2197a21439b26","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"8ed4d88b83087a45f85eb33564316a30c8af5f3cb1bf4b028ca33f71f7f23da9","parent":"51af63b1e935014b46eb9f339c6490a42e5929ceb3c630fda79e865f1a9f8434","source":"0001213900-26-023063","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":391,"hourly_limit":500,"remaining":109,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}